ANA MARIA
MUÑOZ PATIÑO
Profesora titular de universidade
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas
Madrid, EspañaPublikationen in Zusammenarbeit mit Forschern von Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (21)
2024
-
Non-HLA angiotensin-type-1 receptor autoantibodies mediate the long-term loss of grafted neurons in Parkinson’s disease models
Stem Cell Research and Therapy, Vol. 15, Núm. 1
2023
-
Boolean analysis shows a high proportion of dopamine D2 receptors interacting with adenosine A2A receptors in striatal medium spiny neurons of mouse and non-human primate models of Parkinson's disease
Neurobiology of Disease, Vol. 188
-
Interactions between Angiotensin Type-1 Antagonists, Statins, and ROCK Inhibitors in a Rat Model of L-DOPA-Induced Dyskinesia
Antioxidants, Vol. 12, Núm. 7
-
The cannabinoid CB1 receptor interacts with the angiotensin AT2 receptor. Overexpression of AT2-CB1 receptor heteromers in the striatum of 6-hydroxydopamine hemilesioned rats
Experimental Neurology, Vol. 362
2022
2021
-
Diabetes, insulin and new therapeutic strategies for Parkinson's disease: Focus on glucagon-like peptide-1 receptor agonists
Frontiers in Neuroendocrinology, Vol. 62
-
Nadph-oxidase, rho-kinase and autophagy mediate the (Pro)renin-induced pro-inflammatory microglial response and enhancement of dopaminergic neuron death
Antioxidants, Vol. 10, Núm. 9
-
Novel Interactions Involving the Mas Receptor Show Potential of the Renin–Angiotensin system in the Regulation of Microglia Activation: Altered Expression in Parkinsonism and Dyskinesia
Neurotherapeutics, Vol. 18, Núm. 2, pp. 998-1016
2020
-
Angiotensin AT1and AT2receptor heteromer expression in the hemilesioned rat model of Parkinson's disease that increases with levodopa-induced dyskinesia
Journal of Neuroinflammation, Vol. 17, Núm. 1
-
Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson’s Disease and Adverse Effects of L-DOPA
Frontiers in Neuroanatomy, Vol. 14
-
Rho kinase inhibitor fasudil reduces l-DOPA-induced dyskinesia in a rat model of Parkinson's disease
British Journal of Pharmacology, Vol. 177, Núm. 24, pp. 5622-5641
2018
-
Physical exercise improves aging-related changes in angiotensin, IGF-1, SIRT1, SIRT3, and VEGF in the substantia Nigra
Journals of Gerontology - Series A Biological Sciences and Medical Sciences, Vol. 73, Núm. 12, pp. 1594-1601
2017
-
BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats
Experimental Neurology, Vol. 297, pp. 73-81
2016
-
Hints on the Lateralization of Dopamine Binding to D
1
Receptors in Rat Striatum
Molecular Neurobiology, Vol. 53, Núm. 8, pp. 5436-5445
-
Aging-related Increase in Rho Kinase Activity in the Nigral Region is Counteracted by Physical Exercise
Journals of Gerontology - Series A Biological Sciences and Medical Sciences, Vol. 71, Núm. 10, pp. 1254-1257
-
Effects of rho kinase inhibitors on grafts of dopaminergic cell precursors in a rat model of Parkinson’s disease
Stem Cells Translational Medicine, Vol. 5, Núm. 6, pp. 804-815
2015
-
Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia
Molecular Neurobiology, Vol. 52, Núm. 3, pp. 1408-1420
2014
-
Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1β
Experimental Neurology, Vol. 261, pp. 720-732
2010
-
Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: Implications for progression of Parkinson's disease
European Journal of Neuroscience, Vol. 32, Núm. 10, pp. 1695-1706
2009
-
Brain oxidative stress and selective behaviour of aluminium in specific areas of rat brain: Potential effects in a 6-OHDA-induced model of Parkinson's disease
Journal of Neurochemistry, Vol. 109, Núm. 3, pp. 879-888